| | PT2 | |
---|
Luminal A | Luminal B HER2- | Luminal B HER2 + | Non-luminal HER2 + | TNBC | Total |
---|
PT1 | Luminal A | - | 9 (2)a,c | 5 (4)a,c | - | 1 (1)a,c | 15 (7) |
Luminal B HER2- | 21b | - | 2 (2)a,c | - | - | 23 (2) |
Luminal B HER2 + | 4b | 2b | - | 1a | - | 7 |
Non-luminal HER2 + | 1b,c | - | - | - | - | 1 |
TNBC | 1 (1)b,c | 1 (1)b,c | - | - | - | 2 (2) |
Total | 27 (1) | 12 (3) | 7 (6) | 1 | 1 (1) | 48 (11) |
- Data are presented as number of patients with discordant subtypes (number of patients where therapy was added due to discordance in PT2)
- HER2 Human epidermal growth factor 2, TNBC Triple-negative breast cancer, PT Primary tumor
- amore aggressive molecular surrogate subtype change in PT2 compared to PT1
- bless aggressive molecular surrogate subtype change in PT2 compared to PT1
- cpatients with potential therapy changes